Sumitomo Pharma America, Inc.
15 drugs in NADAC|0 Generic,15 Brand
Sumitomo Pharma America, Inc. lists 15 NDCs in the CMS NADAC file (0 generic, 15 brand), at an average NADAC of $42.41 per unit, with a week-over-week move of +0.0% across products that moved. The firm's full portfolio, pricing trend are listed below.
Total Drugs
15
0G / 15B
Avg Price / Unit
$42.4128
$16.46 – $69.28
Avg 7d Change
+0.03%
Across 9 drugs with changes
7d Activity
of 15 total drugs
Portfolio Price Trend
Monthly average NADAC price across all drugs
Keep following this manufacturer
These next-step links connect the manufacturer page to the markets, classes, and trend views most likely to deepen research.
Lead market
lurasidone hydrochloride market
See the molecule this manufacturer shows up in most often and compare it against competing suppliers.
Lead class
Atypical Antipsychotic therapeutic class
Review the broader class where Sumitomo Pharma America, Inc. has the strongest current portfolio footprint.
Trend hub
Portfolio trend view
Jump to the trend hub to compare this manufacturer against the rest of the market on weekly price movement.
Guide
NADAC pricing primer
Use the explainer for context on the benchmark this manufacturer is being compared against.
Frequently Asked Questions
How many drugs does Sumitomo Pharma America, Inc. make?
Sumitomo Pharma America, Inc. lists 15 NDCs in the CMS NADAC file — 0 generic and 15 brand products.
What is the average price of Sumitomo Pharma America, Inc. drugs?
The average NADAC across Sumitomo Pharma America, Inc.'s portfolio is $42.4128 per unit, ranging from $16.4598 to $69.2795.
What types of drugs does Sumitomo Pharma America, Inc. make?
Sumitomo Pharma America, Inc. makes drugs across 5 FDA pharmacologic classes. The most common by NDC count are Atypical Antipsychotic (8), beta3-Adrenergic Agonist (2), Estrogen (1), Gonadotropin Releasing Hormone Receptor Antagonist (1), Progestin (1).
Has Sumitomo Pharma America, Inc. had any drug recalls?
No FDA enforcement recalls are matched to Sumitomo Pharma America, Inc. in the openFDA feed.
How has Sumitomo Pharma America, Inc.'s pricing changed recently?
Over the past 7 days, 6 Sumitomo Pharma America, Inc. products rose and 3 fell, with a portfolio-wide average change of +0.0%.
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
LATUDA 120 MG TABLET lurasidone hydrochloride | $69.2795 per EA | — |
LATUDA 40 MG TABLET lurasidone hydrochloride | $47.1131 per EA | +0.30% |
LATUDA 60 MG TABLET lurasidone hydrochloride | $46.8109 per EA | +0.02% |
LATUDA 20 MG TABLET lurasidone hydrochloride | $46.4567 per EA | — |
LATUDA 80 MG TABLET lurasidone hydrochloride | $46.3695 per EA | +0.01% |
MYFEMBREE 40 MG-1 MG-0.5 MG TB relugolix, estradiol hemihydrate, and norethindrone acetate | $45.2514 per EA | -0.01% |
APTIOM 600 MG TABLET ESLICARBAZEPINE ACETATE | $44.4261 per EA | +0.05% |
APTIOM 200 MG TABLET ESLICARBAZEPINE ACETATE | $44.2430 per EA | — |
APTIOM 800 MG TABLET ESLICARBAZEPINE ACETATE | $44.1667 per EA | -0.05% |
APTIOM 400 MG TABLET ESLICARBAZEPINE ACETATE | $44.0071 per EA | -0.07% |
LATUDA 40 MG TABLET lurasidone hydrochloride | $43.0175 per EA | — |
LATUDA 80 MG TABLET lurasidone hydrochloride | $43.0125 per EA | — |
LATUDA 60 MG TABLET lurasidone hydrochloride | $39.1179 per EA | — |
GEMTESA 75 MG TABLET vibegron | $16.4597 per EA | +0.01% |
GEMTESA 75 MG TABLET vibegron | $16.4597 per EA | +0.01% |